Overview

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
Valneva Austria GmbH
Treatments:
Vaccines